Aggregation response at the end of the aggregation curve and maximum velocity of patients undergoing antiplatelet treatment using native and adjusted PRP
| Patient | Age (years) | Sex | Antiplatelet treatment | Platelets/nl in native and adjusted PRP | Aggregation response at end of aggregation (%)* | Max. velocity (mE/sec) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| ADP | COL | ARA | ADP | COL | ARA | |||||
| *des, desaggregation in %. | ||||||||||
| ARA, arachidonic acid; ASA, acetylsalicylic acid; C, clopidogrel; COL, collagen; PRP, platelet rich plasma. | ||||||||||
| 1 | 56 | M | ASA | Native: 320 | 15 (des: 75) | 89 | 6 | 40 | 25 | 3 |
| Adjusted: 255 | 10 (des: 70) | 80 | 5 | 30 | 21 | 2 | ||||
| 2 | 58 | M | ASA | Native: 639 | 45 (des: 30) | 87 | 16 | 38 | 29 | 53 |
| Adjusted: 268 | 35 (des: 10) | 76 | 14 | 12 | 10 | 32 | ||||
| 3 | 66 | F | ASA | Native: 364 | 60 (des: 10) | 76 | 35 | 23 | 16 | 5 |
| Adjusted: 265 | 52 (des: 13) | 68 | 22 | 12 | 8 | 2 | ||||
| 4 | 80 | F | ASA | Native: 382 | 50 (des: 16) | 80 | 38 | 21 | 14 | 4 |
| Adjusted: 253 | 55 | 68 | 30 | 10 | 7 | 2 | ||||
| 5 | 41 | F | ASA | Native: 600 | 46 (des: 30) | 87 | 17 | 39 | 24 | 3 |
| Adjusted: 265 | 44 (des: 20) | 82 | 20 | 14 | 8 | 3 | ||||
| 6 | 64 | F | C | Native: 717 | 50 (des: 20) | 83 | 79 | 37 | 31 | 44 |
| Adjusted: 250 | 20 (des: 20) | 86 | 27 (des: 20) | 12 | 11 | 10 | ||||
| 7 | 46 | F | ASA | Native: 500 | 60 (des: 25) | 84 | 11 | 49 | 29 | 7 |
| Adjusted: 244 | 54 (des: 15) | 79 | 18 | 18 | 12 | 3 | ||||
| 8 | 78 | F | ASA+C | Native: 393 | 1 (des: 12) | 55 | 3 | 10 | 16 | 1 |
| Adjusted: 248 | 2 (des: 10) | 52 | 4 | 8 | 10 | 1 | ||||
| 9 | 68 | M | ASA | Native: 559 | 21 (des: 15) | 56 | 21 | 21 | 18 | 4 |
| Adjusted: 256 | 25 (des: 17) | 52 | 21 | 11 | 10 | 6 | ||||
| 10 | 66 | F | ASA+C | Native: 442 | 59 (des: 20) | 79 | 25 | 33 | 12 | 8 |
| Adjusted: 260 | 55 (des: 15) | 79 | 31 | 16 | 11 | 3 | ||||